Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Amplify Transformational Data Sharing ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Amplify Transformational Data Sharing ETF trades at $61.14. Which is the better fit depends on your goals.
| BIO | BLOK | |
|---|---|---|
Market Cap | $8.02B | — |
Sector | Health | — |
52-Week High | $339.75 | $74.10 |
52-Week Low | $241.71 | $47.36 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BLOK trades at $60.81, down 2.95% on the day, with a bearish technical signal from moving averages while oscillators are neutral. The stock faces resistance near $62 and support at $60. Recent news highlights its diversified blockchain economy exposure, including miners and enterprise adopters, though financial ratios like P/E and P/S are not provided in the current dataset.
The outlook remains cautious due to technical bearishness and increased reliance on Bitcoin performance, posing volatility risks. Investment opportunity lies in broad blockchain sector exposure, but risks include market sentiment shifts and lack of near-term catalysts, warranting close monitoring of earnings and sector trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
